Immunocore, Ltd.
http://www.immunocore.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Immunocore, Ltd.
Finance Watch: Alto, Fractyl Bring IPO Count To Four, So Far, In 2024
Public Company Edition: Alto Neuroscience and Fractyl Health grossed $128.6m and $110m, respectively, while FibroBiologics went public in a direct listing. Also, Vaxcyte grossed $862.5m in a follow-on offering, Immunocore grossed $350m in a note sale and Vera raised $287.5m.
J.P. Morgan 2024: Optimism With An Undercurrent Of Tension
An uptick in deals and an improving macro-economic outlook laid the groundwork for a rosier sentiment across much of the industry at the annual health care conference.
UK's T-Therapeutics Raises Almost $60m Despite Tough Funding Environment
CEO Allan Bradley tells Scrip that “we're at the very beginning of what I believe will be an explosion of TCR-based therapeutics” and his start-up hopes to take a leading position.
Project Orbis: More Cancer Drugs Available In Scotland Than England
The UK joined Project Orbis in 2021 with the aim of speeding up the regulatory process for promising cancer drugs, but fewer than half of the drugs licensed under this pathway are available on the NHS in England.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
-
Large Molecule
- Antibodies
-
Drug Discovery Technologies
- ADMET
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice